Revenue
2018
DiaMedica Therapeutics Inc. (DMAC)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $500,000 | — |
| Research & development | $24.6M | $19.1M | $13.1M | $7.8M | $8.8M | $8.2M | $7.9M | $4.5M | $3.2M |
| Operating expenses | $34.4M | $26.7M | $21.3M | $14.0M | $13.6M | $12.7M | $11.6M | $7.3M | $4.5M |
| Operating income | −$34.4M | −$26.7M | −$21.3M | −$14.0M | −$13.6M | −$12.7M | −$11.6M | −$6.8M | −$4.5M |
| Net income | −$32.8M | −$24.4M | −$19.4M | −$13.7M | −$13.6M | −$12.3M | −$10.6M | −$5.7M | −$4.3M |
| Basic EPSper diluted share | -$0.70 | -$0.60 | -$0.60 | -$0.52 | -$0.65 | -$0.78 | -$0.89 | -$0.74 | -$0.72 |
| Diluted EPSper diluted share | — | — | — | — | -$0.65 | -$0.78 | -$0.89 | -$0.74 | -$0.72 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 25, 2025Form 4 | TRILL AB +1TenPercentOwner | BuyCommon Shares · indirect | 73.1K | $8.57 | $626.5K | 8.83M |
| Nov 24, 2025Form 4 | TRILL AB +1TenPercentOwner | BuyCommon Shares · indirect | 40.3K | $7.89 | $317.6K | 8.75M |
| Nov 21, 2025Form 4 | TRILL AB +1TenPercentOwner | BuyCommon Shares · indirect | 208.9K | $7.41 | $1.55M | 8.71M |
| Nov 20, 2025Form 4 | TRILL AB +1TenPercentOwner | BuyCommon Shares · indirect | 128.4K | $7.41 | $951.6K | 8.50M |
| Nov 19, 2025Form 4 | TRILL AB +1TenPercentOwner | BuyCommon Shares · indirect | 240.4K | $7.21 | $1.73M | 8.38M |